85 related articles for article (PubMed ID: 8206195)
1. [Cost benefit of screening for type 1 diabetes. A futuristic scenario].
Lévy-Marchal C
Diabete Metab; 1993 Dec; 19(5 Suppl):538-45. PubMed ID: 8206195
[TBL] [Abstract][Full Text] [Related]
2. [Predictive genetic screening for type-1 diabetes in the Hungarian population].
Hermann R; Soltész G
Orv Hetil; 2004 Feb; 145(7):337-42. PubMed ID: 15049049
[TBL] [Abstract][Full Text] [Related]
3. [Cost of insulin-dependent diabetes vs cost of its prevention].
Vardi P; Weitzman S; Shavit T
Harefuah; 1995 Mar; 128(5):281-5, 335. PubMed ID: 7744348
[TBL] [Abstract][Full Text] [Related]
4. The importance of diabetes registries and clinical biology for the study and treatment of type 1 (insulin-dependent) diabetes mellitus.
Gorus FK
Verh K Acad Geneeskd Belg; 1996; 58(5):539-86. PubMed ID: 9008403
[TBL] [Abstract][Full Text] [Related]
5. Islet autoantibodies, nationality and gender: a multinational screening study in first-degree relatives of patients with Type I diabetes.
Williams AJ; Bingley PJ; Moore WP; Gale EA;
Diabetologia; 2002 Feb; 45(2):217-23. PubMed ID: 11935153
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic islet cell antibodies remain valuable in defining risk of progression to type 1 diabetes in subjects with other islet autoantibodies.
Pietropaolo M; Yu S; Libman IM; Pietropaolo SL; Riley K; LaPorte RE; Drash AL; Mazumdar S; Trucco M; Becker DJ
Pediatr Diabetes; 2005 Dec; 6(4):184-92. PubMed ID: 16390386
[TBL] [Abstract][Full Text] [Related]
7. Study of islet cell antibodies as predictive marker of type 1 diabetes.
Mitrea MC; Cojocaru M
Rom J Intern Med; 1998; 36(3-4):261-5. PubMed ID: 10822523
[TBL] [Abstract][Full Text] [Related]
8. [Preventative biology of type 1 diabetes: implications for clinical preventative studies].
Gorus FK; Weets I; Decochez K; van der Auwera BJ
Verh K Acad Geneeskd Belg; 2003; 65(4):203-29; discussion 229-31. PubMed ID: 14534938
[TBL] [Abstract][Full Text] [Related]
9. [Prevalence and predictive value of GAD65 autoantibodies and their correlation with HLA DR-DQ genotypes in children with type-1 diabetes].
Hermann R; Gombos Z; Gyürüs E; Soltész G
Orv Hetil; 2003 Feb; 144(8):355-60. PubMed ID: 12666382
[TBL] [Abstract][Full Text] [Related]
10. Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes.
Truyen I; De Grijse J; Weets I; Kaufman L; Pipeleers L; Nanos N; Decochez K; Hilbrands R; Kaufman JM; Keymeulen B; Mathieu C; Van Gaal L; Pipeleers DG; Gorus FK;
Clin Exp Immunol; 2007 Aug; 149(2):243-50. PubMed ID: 17521324
[TBL] [Abstract][Full Text] [Related]
11. Prediction and diagnosis of type 1 diabetes using beta-cell autoantibodies.
Batstra MR; Aanstoot HJ; Herbrink P
Clin Lab; 2001; 47(9-10):497-507. PubMed ID: 11596913
[TBL] [Abstract][Full Text] [Related]
12. Young age and HLA markers enhance the risk of progression to type 1 diabetes in antibody-positive siblings of diabetic children.
Yamamoto AM; Deschamps I; Garchon HJ; Roussely H; Moreau N; Beaurain G; Robert JJ; Bach JF
J Autoimmun; 1998 Dec; 11(6):643-50. PubMed ID: 9878086
[TBL] [Abstract][Full Text] [Related]
13. [Genetic and immunologic risks for development of type 1 diabetes--experiences from an intervention trial].
Undlien DE; Joner G; Dahl-Jørgensen K; Rønningen KS; Nicol-Smith L; Torjesen PA; Søvik O
Tidsskr Nor Laegeforen; 2000 Sep; 120(23):2799-803. PubMed ID: 11107929
[TBL] [Abstract][Full Text] [Related]
14. [Type 1 diabetes: origin and possibilities for prevention].
Mathieu C; Decallonne B; Casteels K
Verh K Acad Geneeskd Belg; 2000; 62(5):423-36; discussion 436-7. PubMed ID: 11144689
[TBL] [Abstract][Full Text] [Related]
15. Genetic screening for individuals at high risk for type 1 diabetes in the general population using HLA Class II alleles as disease markers. A comparison between three European populations with variable rates of disease incidence.
Hermann R; Bartsocas CS; Soltész G; Vazeou A; Paschou P; Bozas E; Malamitsi-Puchner A; Simell O; Knip M; Ilonen J
Diabetes Metab Res Rev; 2004; 20(4):322-9. PubMed ID: 15250035
[TBL] [Abstract][Full Text] [Related]
16. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.
Mahon JL; Sosenko JM; Rafkin-Mervis L; Krause-Steinrauf H; Lachin JM; Thompson C; Bingley PJ; Bonifacio E; Palmer JP; Eisenbarth GS; Wolfsdorf J; Skyler JS; ;
Pediatr Diabetes; 2009 Apr; 10(2):97-104. PubMed ID: 18823409
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T
Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690
[TBL] [Abstract][Full Text] [Related]
18. Costs of predicting IDDM.
Hahl J; Simell T; Ilonen J; Knip M; Simell O
Diabetologia; 1998 Jan; 41(1):79-85. PubMed ID: 9498634
[TBL] [Abstract][Full Text] [Related]
19. [Is prevention of type I diabetes mellitus feasible?].
Thivolet C
Diabete Metab; 1994; 20(2 Pt 2):235-9. PubMed ID: 8001710
[TBL] [Abstract][Full Text] [Related]
20. Signs of beta-cell autoimmunity and HLA-defined diabetes susceptibility in the Finnish population: the sib cohort from the Type 1 Diabetes Prediction and Prevention Study.
Kukko M; Kimpimäki T; Kupila A; Korhonen S; Kulmala P; Savola K; Simell T; Keskinen P; Ilonen J; Simell O; Knip M
Diabetologia; 2003 Jan; 46(1):65-70. PubMed ID: 12637984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
